Next Article in Journal
Thirty-Five Years of Computerized Cognitive Assessment of Aging—Where Are We Now?
Next Article in Special Issue
Glutathione Blood Concentrations: A Biomarker of Oxidative Damage Protection during Cardiopulmonary Bypass in Children
Previous Article in Journal
A Potential Application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Combined with Photodynamic Diagnosis for the Detection of Bladder Carcinoma in Situ: Toward the Future ‘MRI-PDD Fusion TURBT’
Previous Article in Special Issue
The HD-OCT Study May Be Useful in Searching for Markers of Preclinical Stage of Diabetic Retinopathy in Patients with Type 1 Diabetes
Open AccessArticle

An Easy and Reliable Strategy for Making Type I Interferon Signature Analysis Comparable among Research Centers

1
Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy
2
Clinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health—IRCCS “Burlo Garofolo”, 34137 Trieste, Italy
3
Department of Paediatrics, Institute for Maternal and Child Health—IRCCS “Burlo Garofolo”, 34137 Trieste, Italy
4
Department of Advanced Diagnostic and Clinical Trials, Institute for Maternal and Child Health—IRCCS “Burlo Garofolo”, 34137 Trieste, Italy
*
Author to whom correspondence should be addressed.
Diagnostics 2019, 9(3), 113; https://doi.org/10.3390/diagnostics9030113
Received: 9 August 2019 / Revised: 30 August 2019 / Accepted: 3 September 2019 / Published: 4 September 2019
(This article belongs to the Special Issue Diagnosis and Management of Pediatric Diseases)
Interferon-stimulated genes (ISGs) are a set of genes whose transcription is induced by interferon (IFN). The measure of the expression of ISGs enables calculating an IFN score, which gives an indirect estimate of the exposition of cells to IFN-mediated inflammation. The measure of the IFN score is proposed for the screening of monogenic interferonopathies, like the Aicardi-Goutières syndrome, or to stratify subjects with systemic lupus erythematosus to receive IFN-targeted treatments. Apart from these scenarios, there is no agreement on the diagnostic value of the score in distinguishing IFN-related disorders from diseases dominated by other types of cytokines. Since the IFN score is currently measured in several research hospitals, merging experiences could help define the potential of scoring IFN inflammation in clinical practice. However, the IFN score calculated at different laboratories may be hardly comparable due to the distinct sets of IFN-stimulated genes assessed and to different controls used for data normalization. We developed a reliable approach to minimize the inter-laboratory variability, thereby providing shared strategies for the IFN signature analysis and allowing different centers to compare data and merge their experiences. View Full-Text
Keywords: interferon signature score; inter-laboratory variability; data sharing; systemic lupus erythematosus; interferonopathies; biostatistics interferon signature score; inter-laboratory variability; data sharing; systemic lupus erythematosus; interferonopathies; biostatistics
Show Figures

Figure 1

MDPI and ACS Style

Pin, A.; Monasta, L.; Taddio, A.; Piscianz, E.; Tommasini, A.; Tesser, A. An Easy and Reliable Strategy for Making Type I Interferon Signature Analysis Comparable among Research Centers. Diagnostics 2019, 9, 113.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop